Zelira Therapeutics (FRA:G1G) FFO


FRA:G1G Zelira Therapeutics Ltd FRA:G1G
1 GF Score
Price €0.30
GF Value €0.07
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:G1G
1GF Score
Zelira Therapeutics Ltd FRA:G1G
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zelira Therapeutics (FRA:G1G) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of €0.30 is trading 328.6% above its estimated GF Value™ of €0.07.

Key valuation signals for FRA:G1G:

  • FFO:
  • GF Value™: €0.07 vs. price of €0.30 (328.6% above fair value)
  • GF Score™: 1/100 with 7 warning signs

No single metric tells the full story. See the FRA:G1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
1GF Score

Get the complete analysis for FRA:G1G

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.07
GF Value